Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

BACKGROUND: NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective ATP-competitive inhibitor of TRK kinases and has demonstrated activity in patients with tumours harbouring NTRK gene fusions. PATIENTS AND METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, D S, Bauer, T M, Lee, J J, Dowlati, A, Brose, M S, Farago, A F, Taylor, M, Shaw, A T, Montez, S, Meric-Bernstam, F, Smith, S, Tuch, B B, Ebata, K, Cruickshank, S, Cox, M C, Burris, H A, Doebele, R C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386027/
https://www.ncbi.nlm.nih.gov/pubmed/30624546
http://dx.doi.org/10.1093/annonc/mdy539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386027/
https://www.ncbi.nlm.nih.gov/pubmed/30624546
http://dx.doi.org/10.1093/annonc/mdy539

Ejemplares similares